![]() |
|
![]() |
![]() |
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
Sponsored by: |
Hospices Civils de Lyon |
Information provided by: | Hospices Civils de Lyon |
ClinicalTrials.gov Identifier: | NCT00132509 |
Data from the literature have suggested that a longer time of thrombolysis might be more effective in ischemic stroke. We, the investigators at Hospices Civils de Lyon, have designed a randomized protocol to test this hypothesis. Moreover, the therapeutic window is 7 hours.
Rt-PA (alteplase) is injected intravenously in the 2 arms of the study for a duration of 60 minutes in the arm with a "classical dose" and 90 minutes in the arm with a "low dose-longer infusion".
This is a study of the outcome at 90 days.
Condition | Intervention | Phase |
Stroke, Acute |
Drug: alteplase 0.9mg/kg over 60 minutes Drug: alteplase 0.8mg/kg over 90 minutes |
Phase II |
MedlinePlus related topics: | Hospice Care |
Drug Information available for: | Alteplase Tissue-type plasminogen activator |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Single Blind, Active Control, Parallel Assignment |
Official Title: | Comparison of the Classical rt-PA Procedure (0.9mg/kg Over 60 Minutes) With a Longer Procedure With Lower Dose (0.8mg/kg Over 90 Minutes) in Acute Ischemic Stroke |
Ages Eligible for Study: | 18 Years to 81 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
Exclusion Criteria:
Study ID Numbers: | 2000.208 |
First Received: | August 19, 2005 |
Last Updated: | June 11, 2008 |
ClinicalTrials.gov Identifier: | NCT00132509 |
Health Authority: | France: Afssaps - French Health Products Safety Agency |
|
|
|
|
|
![]() |